In vitro interaction of ceftazidime–avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates

International Journal of Infectious Diseases

Volumn 65, Issue , 2017, Pages 1-3

  Gaibani, Paolo ^a   Lewis, Russell E ^a,b   Volpe, Silvia L ^a   Giannella, Maddalena ^a,b   Campoli, Caterina ^a   Landini, Maria Paola ^c   Viale, PierLuigi ^a,b   Re, Maria Carla ^a,b   Ambretti, Simone ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Carbapenem; Ceftazidime avibactam; Imipenem; KPC producing Klebsiella pneumoniae; Synergy

Indexed keywords

AVIBACTAM; BACTERIAL ENZYME; CARBAPENEMASE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; TIGECYCLINE; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAM; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; MINOCYCLINE; THIENAMYCIN DERIVATIVE;

ALLELE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG POTENCY; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION INDEX; GENE MUTATION; GENETIC ANALYSIS; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HUMAN; ITALY; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMS; CEFTAZIDIME; CEPHALOSPORINS; GENTAMICINS; HUMANS; IMIPENEM; ITALY; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; THIENAMYCINS;

EID: 85031109290     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2017.09.017     Document Type: Article

References (12)

1. Camargo, J.F., Simkins, J., Beduschi, T., Tekin, A., Aragon, L., Pérez-Cardona, A., et al. Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 59 (2015), 5903–5908.
2. Cannatelli, A., D'Andrea, M.M., Giani, T., Di Pilato, V., Arena, F., Ambretti, S., et al. In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob Agents Chemother 57 (2013), 5521–5526.
3. EUCAST, Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1. 2016 http://www.eucast.org/clinical_breakpoints/.
4. Gaibani, P., Lombardo, D., Lewis, R.E., Mercuri, M., Bonora, S., Landini, M.P., et al. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother 69 (2014), 1856–1865.
5. Haidar, G., Clancy, C.J., Shields, R.K., Hao, B., Cheng, S., Nguyen, M.H., Mutations in bla(KPC-3) that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases. Antimicrob Agents Chemother, 61, 2017 pii: e02534-16.
6. Milne, K.E., Gould, I.M., Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J Antimicrob Chemother 65 (2010), 82–90.
7. Munoz-Price, L.S., Poirel, L., Bonomo, R.A., Schwaber, M.J., Daikos, G.L., Cormican, M., et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13 (2013), 785–796.
8. Pitout, J.D., Nordmann, P., Poirel, L., Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59 (2015), 5873–5884.
9. Shields, R.K., Potoski, B.A., Haidar, G., Hao, B., Doi, Y., Chen, L., et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae Infections. Clin Infect Dis 63 (2016), 1615–1618.
10. (KPC-3) mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother, 61, 2017 pii: e02097-16.
11. Temkin, E., Torre-Cisneros, J., Beovic, B., Benito, N., Giannella, M., Gilarranz, R., et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother, 61, 2017 pii:e01964-16.
12. Wu, G., Abraham, T., Lee, S., Ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis 63 (2016), 1147–1148.